ALLMedicine™ Male Breast Cancer Center

Apr 28th, 2022 - Male breast cancer is a rare malignant tumor, and outcomes of breast conservation therapy (BCT) are currently lacking. The retrospective, population-based cohort study included 1369 stage I-II (T1-2 N0-1 M0) male breast cancer patients from the SE...

Apr 7th, 2022 - Re: 'Occupational rehabilitation of male breast cancer patients: Return patterns, motives, experiences, and implications-A qualitative study'.|2022|Que WQ,Li JM,Tang J,Zhao JY,Su XQ,|

Mar 29th, 2022 - The treatment of male breast cancer (MBC) has been extrapolated from female breast cancer (FBC) because of its rarity despite their different clinicopathologic characteristics. We aimed to investigate the distribution of intrinsic subtypes based o...

Feb 25th, 2022 - Breast cancer is a well-recognised late adverse effect in female childhood cancer survivors (CCSs), especially after chest radiotherapy; information on subsequent male breast cancer (SMBC) is limited. We summarised the existing evidence on SMBC af...

Feb 22nd, 2022 - Male breast cancer (MBC) is often diagnosed at a later stage and with a more unfavorable tumor-to-breast ratio compared to women, prompting lower rates of breast conservation (BCT). We sought to assess the practice patterns of neoadjuvant therapy ...

Feb 15th, 2020 - To develop recommendations concerning the management of male breast cancer. ASCO convened an Expert Panel to develop recommendations based on a systematic review and a formal consensus process. Twenty-six descriptive reports or observational studi...

Oct 6th, 2021 - Marissa Howard-McNatt, MD Director, Breast Care Center, Associate Professor Surgery, Comprehensive Cancer Center at Wake Forest Baptist Determination of BRCA1 and 2 mutation carrier status has become increasingly important. Estimates ...

Apr 2nd, 2021 - Transcript: Andrew D. Seidman, MD: So, this also begs the question of, do we have molecular markers that can help us decide when endocrine resistance has occurred? Can you talk a little bit about what we know, what’s the state-of-the-art right...

Apr 2nd, 2021 - Transcript: Joyce A. O’Shaughnessy, MD: Let’s move on to the androgen receptor. Thankfully, we have Tiffany here who can tell us all about it. And, also, of course, you’ve led all the clinical trials, but do you ever get it in standard practic...

Mar 26th, 2021 - Adam M. Brufsky, MD, PhD, a professor of medicine, associate chief in the Division of Hematology/Oncology, co-director of the Comprehensive Breast Cancer, and associate director of clinical investigation at the University of Pittsburgh, discusses ...

Mar 26th, 2021 - Javier Cortés, MD, PhD, head of breast cancer and gynecological cancers at Hospital Universitario Ramón y Cajal, as well as a clinical investigator in the breast cancer research program at Vall d’Hebron Institute of Oncology, discusses the inciden...